Skip to content
  1. ClinicalTrials.gov: newly registered trials60

    NYU Langone registers trial of psilocybin-assisted psychotherapy for fear of cancer recurrence in early-stage breast cancer

    NYU Langone Health has registered a double-blind, parallel-design, placebo-controlled, two-centre randomised controlled trial of single-dose psilocybin-assisted psychotherapy in 100 outpatients with early-stage breast cancer. The trial is designed to evaluate efficacy and psychological mechanisms for fear of cancer recurrence (FCR), anxiety and depression distress and quality of life, comparing a single 25mg oral dose of psilocybin with a single 5mg oral dose as an active placebo, both delivered with a psychotherapy platform.

    Why it matters: The registry record sets out a two-centre design with an active placebo, so readers can see how the trial plans to separate psilocybin from expectancy in fear of cancer recurrence.

  1. FDA: press announcements (US)62

    FDA seeks public input on early-phase ibogaine trial design

    The US Food and Drug Administration has issued a request for information on approaches it is considering for the design of early-phase clinical trials of ibogaine drug products, and is seeking public comment.

    Why it matters: The request sets out the protocol questions the agency wants answered, including a starting dose cap, so researchers and sponsors can see what evidence the FDA expects before early-phase ibogaine trials proceed.

  1. Europe PMC: new psychedelic research papers60

    Systematic review examines the effect of psychedelics on associative learning

    A systematic review of 62 studies, only 2 in humans, reports that psychedelic administration appears to enhance associative learning in animals across conditioning paradigms, though findings were not consistent. The authors write that direct evidence of enhanced associative learning in humans remains limited, while human studies show altered cognitive flexibility and learning-related processes.

    Why it matters: The review separates animal evidence of enhanced associative learning from the limited human data, a distinction that matters for claims about the post-acute window used in psychedelic-assisted psychotherapy.

  1. TGA: interim scheduling decisions (Australia)62

    TGA publishes interim scheduling decisions on Poisons Standard amendments from ACMS #47 and Joint ACMS-ACCS #40

    The TGA has published its interim decisions on proposed amendments to the Poisons Standard considered at ACMS #47 and Joint ACMS-ACCS #40, and invites comment. The closing date for submissions is 10 July 2026. The notice is a summary only and does not list the substances or amendments covered.

    Why it matters: The notice marks the interim stage of scheduling, so anyone with an interest in the proposed Poisons Standard amendments has until 10 July 2026 to comment before a final decision.

  1. TGA: final scheduling decisions (Australia)62

    TGA publishes final Poisons Standard decisions from ACCS #40 and Joint ACMS-ACCS #39

    The TGA has published its notice of final decisions on whether to amend the Poisons Standard, following the Advisory Committee on Chemicals Scheduling (ACCS) #40 and the Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (Joint ACMS-ACCS) #39. The publication is issued under regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990. The feed supplied only a summary, so the specific substances and outcomes are not stated here.

    Why it matters: The notice is the formal record of which scheduling proposals were accepted or rejected, so companies and prescribers can check whether a compound's legal status changed.

  1. Advisory Council on the Misuse of Drugs (UK)62

    UK advisory council publishes updated review of ketamine use and harms

    The Advisory Council on the Misuse of Drugs has published an updated review of the use and harms of ketamine, following a commission from the then Minister for Policing, Fire and Crime Prevention in January 2025. The report reviews prevalence and harms of ketamine and its analogues in the UK, describes legitimate uses including treatment and research, covers emerging health harms such as hepatobiliary toxicity, and describes supply and trafficking.

    Why it matters: The review was commissioned to advise on ketamine's classification, so its findings on prevalence, hepatobiliary toxicity and supply could shape how the UK schedules the drug and its analogues.

You have reached the end